Markets:

Overview

News

Currencies

International

Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

38.56 -0.30 (-0.77%)

Streaming Delayed Price Updated: 10:14 AM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? ↗

July 24, 2026

This late-stage biotech innovator in rare disease therapies reported significant insider selling amid strong one-year share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

Pharvaris NV (NASDAQ:PHVS) Reports Q4 2025 Financial Results and Key Pipeline Milestones ↗

April 02, 2026

Via Chartmill

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.

Via The Motley Fool

Topics Regulatory Compliance

Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 ↗

May 11, 2026

This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid ongoing drug development milestones.

Via The Motley Fool

Topics Regulatory Compliance

For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next ↗

April 29, 2026

This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of strong stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors. ↗

April 13, 2026

This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a year of sharp share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.

Via The Motley Fool

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗

December 09, 2025

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Via The Motley Fool

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Via The Motley Fool

Topics Regulatory Compliance

PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment ↗

December 03, 2025

The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks.

Via Stocktwits

A $68 Million Signal: What General Atlantic Sees in Pharvaris Right Now ↗

December 02, 2025

General Atlantic is building its position just as Pharvaris nears pivotal readouts. This article breaks down what the fund may be anticipating and the signals investors should track next.

Via The Motley Fool

Topics Regulatory Compliance

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

Via The Motley Fool

Topics Regulatory Compliance

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Topics Regulatory Compliance

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

A major biotech investor just walked away from MoonLake after a rough year for the stock. Here’s what that move signals—and what long-term investors should keep an eye on next.

Via The Motley Fool

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

This Uber Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

October 15, 2025

Via Benzinga

Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress ↗

August 12, 2025

Pharvaris NV (PHVS) reported a Q2 2025 loss of €0.83/share, missing estimates. Revenue was nil as R&D spend rose. Focus remains on Phase 3 trials for deucrictibant in HAE/AAE-C1INH, with key data...

Via Chartmill

PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024 ↗

August 14, 2024

PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense ↗

July 16, 2024

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

Via Investor's Business Daily

PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 ↗

May 08, 2024

PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 ↗

April 10, 2024

PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision ↗

January 22, 2024

The company is working on a treatment for swelling attacks associated with a genetic disease.

Via Investor's Business Daily

FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps ↗

January 22, 2024

Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.